Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
4D Molecular Therapeutics, Inc. is a late-stage biotechnology company specializing in innovative genetic medicines for ophthalmology and pulmonology. Its lead product, 4D-150, targets retinal diseases like wet AMD and diabetic macular edema, while 4D-710 aims to treat cystic fibrosis. Utilizing its proprietary Therapeutic Vector Evolution platform, the company addresses significant unmet medical needs, focusing on durable therapies with reduced treatment burdens. 4DMT is positioned for impactful advancements in patient care.
This description was generated via AI from an annual report. Updated about 1 year ago.